Get started
Author

Eric J. Hsu

Observed names: E.J. Hsu, Eric Hsu, Eric J Hsu, Hsu, Eric J, Hsu, Eric J.
Observed institutions: University of Debrecen, Washington University in St. Louis, Boston Biomedical (United States), Stanford Medicine, The University of Texas Southwestern Medical Center, Stanford University
ORCID: 0000-0002-6743-2399
Observed ORCID: 0000-0002-6743-2399
OpenAlex ID: A5031386165
A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
2021 · Eric J. Hsu, Xuezhi Cao, et al. · Nature Communications · 124
PDF
Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
2021 · Xuezhi Cao, Yong Liang, et al. · Nature Communications · 104
PDF
Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells
2021 · Longchao Liu, Jiahui Chen, et al. · Nature Biomedical Engineering · 84
PDF
IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer
2022 · Joonbeom Bae, Longchao Liu, et al. · Nature Cell Biology · 83
Next-generation cytokines for cancer immunotherapy
2021 · Diyuan Xue, Eric Hsu, et al. · Antibody Therapeutics · 80
PDF
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity
2019 · Zhida Liu, Chuanhui Han, et al. · Science Immunology · 41
Direct Measurement of Cardiac Na + Channel Conformations Reveals Molecular Pathologies of Inherited Mutations
2015 · Zoltan Varga, Wandi Zhu, et al. · Circulation Arrhythmia and Electrophysiology · 41
PDF
Regulation of Na+ channel inactivation by the DIII and DIV voltage-sensing domains
2017 · Eric J. Hsu, Wandi Zhu, et al. · The Journal of General Physiology · 32
PDF
Evaluation of Tumor Cell–Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin
2019 · An-Yun Chang, Eric Hsu, et al. · Molecular Cancer Research · 26
Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma
2021 · Raquibul Hannan, Osama Mohamad, et al. · Clinical Cancer Research · 24
Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas
2022 · Eric J. Hsu, Jamie Thomas, et al. · Discover Oncology · 21
PDF
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy
2023 · Alexander D. Sherry, Pavlos Msaouel, et al. · European Journal of Cancer · 20
PDF
Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients
2022 · Eric J. Hsu, Jamie Thomas, et al. · Frontiers in Oncology · 12
PDF
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials
2024 · Eric J Hsu, Timothy A Lin, et al. · JNCI Journal of the National Cancer Institute · 11
3D printed integrated bolus/headrest for radiation therapy for malignancies involving the posterior scalp and neck
2022 · Eric J. Hsu, David Parsons, et al. · 3D Printing in Medicine · 9
PDF
Socioeconomic and demographic determinants of radiation treatment and outcomes in glioblastoma patients
2022 · Eric J. Hsu, Jamie Thomas, et al. · Frontiers in Neurology · 5
PDF
Abstract LB-140: Inhibition of cancer stemness sensitizes colorectal cancer to immune checkpoint inhibitors
2017 · Yuan Gao, Youzhi Li, et al. · Cancer Research · 3
Abstract 2222: Dual inhibition of cancer stemness and immune checkpoint genes by targeting Stat3
2016 · Yuan Gao, Sarah Keates, et al. · Cancer Research · 3
Modeling gamma knife radiosurgical toxicity for multiple brain metastases
2023 · Eric J. Hsu, Yulong Yan, et al. · Radiotherapy and Oncology · 2
PDF
Differential censoring in overall survival in phase 3 oncology clinical trials
2025 · Eric J Hsu, Alexander D Sherry, et al. · JNCI Journal of the National Cancer Institute · 1
Planarian Regeneration in Response to Drug Disruption of the Wnt and MAPK Pathways
2016 · Yong Shen, Thomas Etheridge, et al. · Journal of Student Science and Technology · 1
Comparative outcomes of perioperative and adjuvant immune checkpoint inhibitor therapies in phase 3 resectable cancer trials: a systematic review and meta-analysis
2026 · Eric Hsu · Figshare
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials
2026 · Sherry, Alexander D, Lin, Christine, et al. · UNC Libraries
Association of Differential Censoring with Primary Endpoint Superiority in Radiation Oncology Cooperative Group Trials
2025 · E.J. Hsu, A.D. Sherry, et al. · International Journal of Radiation Oncology*Biology*Physics
Dose-Volume Constraints Associated with Liver Toxicity in Patients with Small Livers Receiving Liver Stereotactic Body Radiation Therapy
2025 · E.J. Hsu, S. Richter, et al. · International Journal of Radiation Oncology*Biology*Physics
Works count: 47
Citation count: 727
H-index: 12
I10-index: 14
Year
Topic
Type